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Objectives: To determine the in vitro resistance of group B streptococcus (GBS) to 12 antibiotics. To determine
if there has been any decrease in sensitivity to the penicillins or other antibiotics currently used for GBS
chemoprophylaxis in pregnant women. Find suitable alternative antibiotics to penicillin. Find an antibiotic that will
have minimal selective pressure for resistance among the endogenous resident vaginal microflora.
Methods: The antibiotic susceptibility profiles of 52 clinical isolates of GBS were evaluated to 12 antibiotics:
ampicillin,azithromycin,cefamandole,cefazolin,ceftriaxone,ciprofloxacin,clindamycin,erythromycin,nitrofuran-
toin, ofloxacin, penicillin and vancomycin. Antibiotic sensitivities were determined using disk diffusion and
microdilution methods according to the guidelines of the National Committee for Clinical Laboratory Standards
(NCCLS).
Results: Allisolatesweresensitivetovancomycin,ofloxacin,ampicillin,ciprofloxacin,nitrofurantoinandpenicillin.
However, the following number of clinical isolates exhibited intermediate or decreased sensitivity, nine (17%) to
ampicillin, eight (15%) to penicillin, 14 (32%) to ciprofloxacin and one (2%) to nitrofurantoin. Thirty-one percent
of the isolates were resistant to azithromycin and ceftriaxone, 19% to clindamycin, 15% to cefazolin and 13% to
cefamandole. Eighteen (35%) of the clinical isolates tested were resistant to 6 of the 12 antibiotics tested.
Conclusions: Therelativelyhighratesofresistancefor6ofthe12antibioticstestedsuggestthatforwomenallergic
to penicillin and colonized with GBS, antibiotic sensitivities to their isolates should be determined. The antibiotic
selected for intrapartum chemoprophylaxis should be guided by the organism’s antibiotic sensitivity pattern.
Patients with GBS bacteriuria should be treated with nitrofurantoin.
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INTRODUCTION
Group B streptococcus (GBS) continues to be
an important cause of both infection and sig-
nificant  morbidity  and  mortality  in  newborns,
and pregnant and non-pregnant women1–3.
Vaginal colonization with GBS reportedly
occurs in 5–35% of women4–7. Thus far GBS
has not posed a significant problem for women
undergoing gynecologic surgery; however, with
the increase in gynecologic surgery occurring in
the older population and the likelihood of these
women having chronic illnesses, GBS poses a
potentially significant threat for the development
of postoperative infection morbidity and
mortality.
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DOI: 10.1080/10647440410001722269Although guidelines for preventing perinatal
transmission of GBS to newborns have been
published, early onset infection continues to be a
problem. In the United States approximately 2200
early onset infections occur yearly8. The incidence
of early onset GBS infection from 1998–1999 was
0.78/1000 live births in African American infants,
0.5/1000 among Hispanic infants and 0.3/1000
among Caucasian infants9.
In a Canadian study, the incidence of GBS in
pregnantwomenwas41/100000and4.1/100000
in non-pregnant adults10. In this study 58.5% of
the cases occurred in women and 14.2% were
associated with pregnancy; 44.2% of the infections
occurred in non-pregnant women. A similar study
conducted in Atlanta, Georgia found an increasing
trend in GBS-invasive disease; in 1982 there were
2.4 cases/100 000 population and in 1993 there
were 5.9/100 0002. In 1992 the incidence of
GBS in pregnant women in Atlanta, Georgia was
22/100 000 and it rose to 66.4/100 000 in 19932.
The spectrum of serious disease caused by GBS
in all age groups initiated the development of a
vaccine11–14.
This study was conducted because of the
significant morbidity and mortality associated with
GBS colonization and infection in newborn
infants, as well as pregnant and non-pregnant
women. Additionally, 13% of women are allergic
to penicillin5,15,16. This should be considered along
with the fact that vaginal colonization rates in
pregnant and non-pregnant women are similar.
Thisandthefactthatoveruseofantibioticsleadsto
the selection of resistant strains were the impetus
for the study. Because of the high rate of antibiotic
exposure for a variety of suspected bacterial infec-
tions, especially the β-lactam antibiotic, macro-
lides and quinolones, the antibiotics select for
resistant strains among the numerous bacteria that
makeuptheendogenousresidentmicrofloraofthe
vagina. Recent studies demonstrated that some
GBS clinical isolates exhibited intermediate or
decreased sensitivity, in vitro, to penicillins17–19.
This decreased sensitivity should not be inter-
preted as resistance but instead be considered
sensitivebecauseitisnottrueresistance.However,
this decrease in sensitivity to penicillin warrants
monitoring of GBS for the possible development
of resistance to penicillins. Thus, this study
was performed to determine the prevalence of
GBS strains among clinical isolates that have
an intermediate sensitivity to the penicillins.
Testing the response of clinical isolates to a variety
of antibiotics would allow for alternative choices
to be used for prophylaxis as well as treatment
of GBS infection for individuals allergic to
penicillin.
METHODS
A total of 52 GBS clinical isolates were examined
from strains stored at −70°C in skim milk (Difco
Laboratories, Detroit) in the Obstetric and Gyne-
cology Infectious Disease Research Laboratory
collection. These isolates were collected from
1998 to 1999. The clinical isolates were obtained
from 45 non-pregnant women (35 vaginal, 10
rectal) and 7 newborns. Because all strains were
stick isolates, each was subcultured three times on
5% sheep blood agar plates (Remel Microbiology
Products,Lenexa,KS).Allisolateswereconfirmed
as GBS on the basis of being Gram-positive cocci,
catalase negative and having a positive latex agglu-
tination assay (Patho Dx Strep Grouping, DPC,
Los Angeles, CA) prior to initiating antibiotic
susceptibility testing.
All procedures for disk susceptibility were
performed in triplicate according to the method-
ologies described in the National Committee for
Clinical Laboratory Standards (NCCLS)20. Fresh
subcultures of GBS were used after overnight
growth (16 h) on blood agar plate. The inoculum
was prepared by suspending several of the colonies
in sterile phosphate buffered saline (pH 7.2)
to achieve a turbidity of 0.5 McFarland
standard, determined by nephelometry. This
resulted in a suspension containing approximately
1–2 × 108 CFU/ml. A sterile cotton swab was
dipped into the bacterial suspension, elevated
above the liquid and rotated several times against
the inside wall of the tube to remove excess
inoculum. The swab was used to inoculate a
150 mm diameter Mueller–Hinton agar plate
supplemented with 5% defibrinated sheep blood.
A second Mueller–Hinton agar plate without
sheep blood was inoculated with a similar
inoculum. The comparison of Mueller–Hinton
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to determine if the sheep blood had an essential
effect on the antibiotic assay.
Eleven disks (Remel Microbiology Products,
Lenexa, KS) were dispensed onto the surface of
the inoculated agar plate. The antibiotics tested
were:10 µgampicillin;15 µgazithromycin;30 µg
cefamandole; 30 µg cefazolin; 30 µg ceftriaxone;
5 µg ciprofloxin; 2 µg clindamycin; 15 µg
erythromycin; 5 µg ofloxacin; 30 µg vancomycin;
and 10 units of penicillin G. One disk containing
300 µg nitrofurantoin (Decton Dickinson Micro-
biology Systems, Cockeysville, MD) was placed
onto the surface of a separate small agar plate. All
plates were inoculated with GBS and incubated at
35°C under 5% CO2 atmosphere for 20 h before
they were read.
The zones of growth inhibition were measured
to the nearest whole millimeter using a sliding
caliper. The sizes of the inhibition zones were
graded according to the NCCLS20. Each isolate
was classified as susceptible, intermediate or resis-
tant to each antibiotic tested. Minimum inhibitory
concentrations (MIC) were determined by the
broth microdilution method recommended by
the NCCLS21. Cation-adjusted Mueller–Hinton
broth (Remel Microbiology Products, Lenexa,
KS) supplemented with 5% lysed horse blood was
used. Suspensions of GBS with a turbidity equiva-
lent to a 0/5 McFarland standard were prepared
as previously described. These suspensions were
further mixed with the supplemental broth at
a 1:200 dilution to obtain a final inoculum con-
centration of 5–10 × 105 CFU/ml. They were
then dispersed into sterile microdilution test
plates (Honeycomb microwell plate, Labsystems,
Finland) prepared with different concentrations
of the antibiotic to be assayed. The plates were
incubated in ambient air at 35°C in a Bioscreen
Analyzer System (Labsystems, Finland). The
optical density of each microwell was measured
automatically at 4-h intervals for 24 h. The MIC
was based on the lowest concentration of each
antibiotic showing complete inhibition of growth.
The isolates were considered susceptible or resis-
tant according to the 1999 interpretive standards
of the NCCLS21. Two systems of antibiotic
susceptibility, disk diffusion and microdilution
or MIC, were used to determine if there was
agreement in the interpretation of results between
the two systems. This was especially true for
those values interpreted as intermediate. In
case of discordance between the results, the
microdilution was considered the most reliable
system.
Vaginal strains resistant and sensitive to clinda-
mycin were screened for genotype. The DNA
extraction and genotyping were determined by
pulse-field gel electrophoresis. Rapid preparation
method of bacterial DNA for pulse-field gel
electrophoresis was used as a standard procedure
withsomemodificationsuitableforGBS22.Isolates
weregrownovernighton5%bloodagar.Allcolo-
nies grown on the blood agar were harvested and
suspended in 2.5 ml of brain-heart infusion broth
(Remel Microbiology Products, Lenexa, KS) and
centrifuged. The pellet of cells was resuspended in
0.5 ml of 1.6% melted agarose and pipetted into a
plug mold to solidify. Then agarose plugs were
incubated sequentially in 3 ml of 1X lysis solution
(5 mg/ml lysozyme containing 30 µg/ml Rnase)
incubated at 37°C with continuous shaking
overnight. They were then placed into 3 ml of
ESP buffer containing proteinase K at 100 µg/ml
and 1% SDS and incubated overnight at 55°C for
1 h. The TE was replaced after 1 h with sterile,
dilute TE and washed with gentle shaking for 1 h.
The TE was replaced with 2 ml of fresh, dilute TE
in a clean tube for storage at 4°C until restriction
digestion. A plug slice 2 to 4 mm wide was placed
in a tube with digestion mixture containing 25 ml
of restriction buffer (Gibco Bethesda Research
Laboratories), 2 µl (20 U) Sma1 (New England
Biolab) and 200 µl distilled water for 24 h at
25°C. After digestion, plugs were loaded into
a 1.2% agarose gel with 0.5X TBE, 89 mM
EDFTAand0.05 µg/mlethidiumbromideusinga
CHEF-DR11apparatus(Bio-RadLaboratories)at
the following parameters: 14C, 200V, switching
time Si = 1s, Sf = 20c, for 21 h.
RESULTS
The results of the antibiotic sensitivities deter-
mined by the agar disk diffusion and microdilution
methods are shown in Tables 1 and 2. The only
difference in susceptibility between the two
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Approximately one-half of the isolates classified
as intermediate-susceptible to ampicillin by disk
diffusion also were found to be susceptible by
the microdilution method. However, eight of 10
strains classified as intermediate sensitive to peni-
cillin G by agar disk diffusion method were found
to maintain this decreased degree of sensitivity by
the microdilution method. Of these, seven isolates
displayed intermediate-sensitivity to ampicillin
(Tables3–5).All10isolatesfoundtoberesistantto
clindamycinbydiskdiffusionwerealsoresistantby
the microdilution method, with a MIC90
≥ 8 µg/ml. Since no differences were found
between the disk diffusion and microdilution
methods, the former can be used when testing
GBS isolates for antibiotic resistance. The only
significant difference (p ≤ 0.019) in measurements
of inhibition zones between the use of Mueller–
Hinton agar, with and without 5% sheep blood,
was found with ciprofloxin.
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Antibiotic Susceptible Intermediate Resistant
Ampicillin
Azithromycin
Cefamandole
Ceftriaxone
Ciprofloxacin
Clindamycin
Erythromycin
Nitrofurantoin
Ofloxacin
Penicillin G
Vancomycin
43 (62.7%)
33 (66.5%)
45 (68.5%)
26 (50%).9
30 (68.2%)
42 (80.8%)
34 (65.4%)
51 (98.1%)
26 (100%)
44 (84.6%)
52 (100%).
9 (17.3%)
3 (5.8%)
0
0
14 (31.8%)
0
5 (9.6%)
1 (1.9%)
0
8 (15.4%)
0
0
16 (30.8%)
7 (13.5%)
8 (15.4%)
0
10 (19.2%)
13 (25%).4
0
0
0
0
*Antibiotic sensitivity testing, both disk diffusion and microdilution methods, followed NCCLS guidelines. Antibiotic cut-off for susceptible
and resistant not found in NCCLS guidelines for Streptococci; used Staphylococcus values as recommended by the NCCLS
Table 1 Susceptibility profile of GBS isolates*
Microdilution*
Disc diffusion Susceptible Intermediate Resistant
Penicillin G intermediate-susceptible
Ampicillin intermediate-susceptible
Clindamycin- resistant
2/10 (20.0%)
10/19 (52.6%)
–
8/10 (80.0%)
9/19 (47.4%)
–
–
–
10/10 (100%)
*According to NCCLS
17
Table 2 Microdilution susceptibility analyzes of GBS isolates determined to intermediate or resistant by disc diffusion
method*
Mueller–Hinton
agar with 5%
sheep blood
Mueller–Hinton
agar without
5% sheep blood p+
Ampicillin
Azithromycin
Cefamandole†
Cefazolin†
Ceftriaxone
Ciprofloxacin†
Clindamycin
Erythromycin
Nitrofurantoin†
Ofloxacin
Penicillin G
Vancomycin
33/52 (63.5%)
33/52 (63.5%)
45/52 (86.5%)
31/34 (91.2%)
26/52 (50.0%)
30/44 (68.2%)
42/52 (80.8%)
34/52 (65.4%)
51/52 (98.1%)
18/18 (100%).
42/52 (80.8%)
52/52 (100%).
32/52 (61.5%)
33/52 (63.5%)
45/52 (86.5%)
32/34 (94.1%)
30/52 (57.7%)
19/44 (43.2%)
43/52 (82.7%)
37/52 (71.2%)
51/52 (98.1%)
16/18 (88.9%)
43/52 (82.7%)
52/52 (100%).
NS
NS
NS
NS
NS
0.019
NS
NS
NS
NS
NS
NS
*According to NCCLS
17
†Antibiotics not found in the NCCLS for Streptococci. Used
Staphylococci values.
+P value based on McNemar test. NS = not significant
Table 3 Comparison of the frequency of disc diffusion
susceptible GBS isolates in Mueller–Hinton agar with and
without 5% sheep blood*DISCUSSION
The use of intrapartum antibiotics to prevent
perinatal vertical transmission of GBS and early-
onset neonatal sepsis has increased significantly
since the Center for Disease Control (CDC) pub-
lishedguidelinesin1996andsubsequentlyreleased
revised guidelines in 20028,23. The current strategy
for prevention estimates that approximately
24–27% of laboring women will receive intra-
partum antibiotics3,4,17,23,24. An estimated 4 million
births occur per year in the United States; there-
fore, approximately 1 million women will be at
risk for GBS colonization and potentially receive
intrapartum antibiotic prophylaxis. The antibiotic
of choice is either penicillin G or ampicillin. The
current CDC guidelines recommend that patients
not allergic to penicillin receive penicillin or
ampicillin. Individuals with a minor allergy to
penicillin should receive cefazolin and individuals
with a major allergy (rash or a history of difficult
breathing) should receive clindamycin or vanco-
mycin if the isolate is known to be resistant to
clindamycin. However, vancomycin has not been
shown to cross the placenta and achieve suitable
concentrations in amniotic fluid as well as the fetal
blood.Thistremendoususeofβ-lactamantibiotics
coupled with the exposure to β-lactams for other
reasons can potentially induce the emergence
of resistant strains among the resident vaginal
microflora. Emergence of resistance has been doc-
umented, especially to ampicillin, e.g. Escherichia
coli16–18. However as documented in several
studies, GBS is universally sensitive to the
penicillins; therefore, it should be the primary
antibiotic for intrapartum prophylaxis3,4.
In this study, as in other studies, strains
of penicillin-resistant GBS were not found. How-
ever, the isolates demonstrated an intermediate
sensitivity to penicillin G in 17% of cases and to
ampicillin in 15% of cases using both the disk
diffusion and micro-tube dilution methods for
determining antibiotic sensitivity. In fact, the disk
diffusion method revealed that 19% of the isolates
had an intermediate sensitivity to penicillin while
36% had an intermediate sensitivity to ampicillin.
Rouse et al. reported that 10% and 8% of the
isolates they tested had intermediate susceptibility
to penicillin and ampicillin respectively17. Betriu
et al. reported that 2% of GBS isolates had an
intermediate susceptibility to penicillin16. Liu et al.
found that 15% of the GBS isolates tested had
an intermediate susceptiblity to penicillin18. The
finding of strains with an intermediate susceptibil-
ity to penicillin G and ampicillin does not mean
that these antibiotics should not be used. How-
ever, this data does indicate that GBS isolates
should be monitored annually to determine if a
decrease in susceptibility emerges, thus leading
to resistance. The continued use of large amounts
of β-lactams will lead to resistance as it has in
Streptococcus pneumoniae.
Furthermore, it has been suggested that the
significant decrease in the incidence of GBS
neonatal sepsis may be accompanied by a rise in
the incidence of Gram-negative neonatal sepsis.
Levine et al. examined the incidence of GBS and
Gram-negative neonatal sepsis prior and subse-
quent to the CDC recommendations. They found
that while the incidence of GBS sepsis declined
significantly, the incidence of Gram-negative
neonatal sepsis increased 4.5 fold in the same
period. Another important observation was that in
all cases of neonatal death caused by sepsis, the
mothers received intrapartum prophylaxis with
ampicillin and the pathogens recovered from the
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ISS* Azithromycin Cefamandole Cefazolin Ceftriaxone Clindamycin Erythromycin
Amp 9
Pen 8
4 (44%)
4 (50%)
6 (67%)
6 (75%)
8 (89%)
7 (87%)
8 (89%)
7 (87%)
7 (78%)
8 (100%)
3 (33%)
2 (25%)
Table 4 Resistance of GBS isolates to other antibiotics among the penicillin intermediate-susceptible strains
Antibiotics* n (%)
1
2
3
4
5
9(33)
6(22)
5(19)
2(4)
4(8)
Table 5 GBS isolates that exhibited
resistance to more than PNE antibioticneonates were resistant to ampicillin3. These find-
ings were similar to other reported cases of adverse
perinatal outcomes with resistant Enterobacteriaceae
after antibiotic usage for premature rupture of
membranes and carriage of GBS25.
Conversely, the data reported by Meyn and
Hillier did not suggest a trend toward reduced
susceptibility for vaginal GBS and E. coli isolates
to ampicillin. They did not find intermediate-
susceptible GBS or any differences in the per-
centage of ampicillin-resistant E. coli during three
years5. Despite these results, some authors have
suggested penicillin G is a better choice than
ampicillin for GBS intrapartum prophylaxis.
Penicillin G has a narrow spectrum of activity
and may be less likely to select resistant
microorganisms than ampicillin3,26.
In the present study GBS isolates were resistant
to: clindamycin (19%), erythromycin (25%) and
cefazolin(15%).Theseresultsarenotverydifferent
from previous reports regarding clindamycin and
erythromycin resistance16,17. However, the rate of
resistance reported in this study was higher than
that reported in other studies. The parameters
used in other studies are not known because the
NCCLS has not published guidelines regarding
sensitivity and resistance for cefazolin for GBS.
The values used in this study were those used for
Staphylococcus species because of the similarity
to GBS and recommended by the NCCLS. In
addition, to ensure that the isolates were not mis-
identified as Enterococcus species, the latex aggluti-
nation antibody–antigen test specific for GBS was
used to confirm that the isolate was GBS.
Representatives of second- and third-
generation cephalosporins were also used, e.g.
cefamandole and ceftriaxone. These antibiotics
also demonstrated a high level of resistance (13%
and30%)anddonotappeartobegoodalternatives
to penicillin. The ability of cephalosporins to
prevent vertical transmission of neonatal GBS
infection has not been studied4.
Other antibiotics tested as possible alternatives
to penicillin showed advantages regarding GBS
susceptibility. In agreement with other published
studies all isolates tested in this study were
susceptible to vancomycin4,16. This antibiotic is
currently the alternative to penicillin in the patient
with a known allergy to penicillin and is also
colonized with a strain of GBS that is resistant
to clindamycin. However the potential toxicity
and concerns about selection of resistance,
especially to Gram-positive cocci, do not make
widespread use of vancomycin a good alternative
at this time. Preliminary data suggest that vanco-
mycin does cross the placenta and achieves
adequate blood levels in the fetus (personal
communication).
The susceptibility of GBS was tested against
nitrofurantoin because it is a good option for the
treatment of both asymptomatic and symptomatic
bacteriuria. Reports regarding the susceptibility
pattern of a large number of GBS isolates to nitro-
furantoin have not been published. No resistance
to nitrofurantoin was found in the GBS isolates
tested in the current study. Unfortunately, nitro-
furantoin cannot be used as an alternative to
penicillin for intrapartum prophylaxis because
effective concentrations are not likely to be
achieved in the maternal blood stream or to cross
the placenta to achieve adequate levels in the fetal
compartment. However, nitrofurantoin is suitable
to treat bacteriuria in the pregnant patient because
ofthehighlevelsachievedintheurine.Italsohasa
good spectrum of activity against Gram-negative
bacteria including E. coli. Nitrofurantoin is
unlikely to have a significant impact on the
endogenous resident microflora and therefore, it
is unlikely that it will select for resistant strains.
In summary, it is not known whether the anti-
biotic resistance demonstrated in vitro has the same
clinical significance in vivo. Future clinical trials are
needed to identify safe and effective alternatives to
penicillin for intrapartum prophylaxis to prevent
perinatal vertical transmission and infection with
GBS. There are probably important regional
variations in GBS antibiotic susceptibilities,
especially for second antibiotics. Therefore, in the
penicillin-allergic patient, the laboratory should
be requested to perform antibiotic sensitivities on
the GBS isolate. This will enable the physician to
choose an appropriate alternative to penicillin.
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